July 2026 – Page 11 – 1stOncology™: Cancer Intelligence Service

Vaxart to Participate in BTIG Biotechnology Conference 2026

On July 21, 2026 Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, reported that members of its management team will participate in the BTIG Virtual Biotechnology Conference taking place virtually July 28, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

BTIG Biotechnology Conference 2026
Date: Tuesday, July 28, 2026
Format: 1×1 Meetings
Location: Virtual

Institutional Investors interested in meeting with Vaxart management should contact their BTIG representative.

(Press release, Vaxart, JUL 21, 2026, View Source [SID1234669361])

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

On July 21, 2026 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") reported publication of results from the ProstACT SELECT study in Cancers, a peer-reviewed journal. The Phase 1 study evaluated TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix’s first-in-class prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy candidate. The study’s scientific purpose was to evaluate lesion concordance between 68Ga-PSMA-PET5 and multi-time point SPECT6 imaging for patient selection using a "theranostic" approach.

The publication highlights TLX591-Tx’s differentiated clinical profile, including an intensified dosing schedule, prolonged tumor retention and low exocrine (salivary) gland irradiation. The authors also concluded that in a heterogeneous population representative of a real-world setting, TLX591-Tx therapy in combination with standard of care (SOC) demonstrated a manageable and predictable safety profile, and indicative efficacy with a median radiographic progression-free survival (rPFS) of 8.8 months reported in evaluable patients.

Nat Lenzo, MD, Nuclear Medicine Oncologist and Principal Investigator on the ProstACT SELECT study commented, "A key objective of ProstACT SELECT was to determine whether PSMA-PET imaging could reliably identify patients suitable for TLX591-Tx therapy, and the results clearly support this approach. The results provide compelling evidence that the PSMA-PET imaging agent and TLX591-Tx are targeting the same disease sites, supporting the ongoing ProstACT Global trial for mCRPC7, where there remains significant unmet need for additional treatment options."

David N. Cade, MD, Group Chief Medical Officer, Telix, said, "The publication of ProstACT SELECT data further strengthens the scientific foundation for Telix’s lead therapeutic candidate, TLX591-Tx. The peer-reviewed results support our patient-selection strategy and demonstrate a differentiated pharmacologic profile characterized by durable tumor targeting, hepatobiliary clearance, and a manageable safety profile. Telix is further evaluating TLX591-Tx in the international multi-center Phase 3 ProstACT Global study, where we aim to meaningfully improve outcomes for patients living with advanced prostate cancer."

The full paper is available at: View Source

About ProstACT SELECT

The purpose of the ProstACT SELECT trial was to evaluate the utility of 68Ga-PSMA-PET imaging (Illuccix) to select patients for TLX591-Tx rADC therapy. The primary objectives were to determine whole body biodistribution and organ radiation dosimetry and assess the safety and tolerability of TLX591-Tx in patients with advanced mCRPC. rPFS was a secondary study objective.

(Press release, Telix Pharmaceuticals, JUL 21, 2026, View Source [SID1234669360])

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

On July 21, 2026 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, reported that the company will deliver an oral presentation and present a poster at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Drug Discovery and Development, or AACR (Free AACR Whitepaper) D3, Conference, taking place July 21–24, 2026 in Boston.

The presentations will highlight the broad and actionable capabilities of the AP3 platform to rapidly identify and advance promising compounds into clinical development, focusing on the discovery of ACR-2316, the company’s novel clinical-stage, selective WEE1/PKMYT1 inhibitor.

Data being presented illustrate how AP3 can uncover drug-induced resistance mechanisms, in this case WEE1 inhibition-induced activation of PKMYT1, resulting in phosphorylation of CDK1 on Thr14, a direct PKMYT1 phosphorylation site. Moreover, AP3 enabled the development of ACR-2316 based on optimal intracellular pathway effects, including sustained activation of CDK1, CDK2, but importantly and also of PLK1, to drive potent pro-apoptotic tumor cell death.

"We are excited to present at AACR (Free AACR Whitepaper) D3 and to highlight the actionable power of our AP3 platform to rapidly translate intracellular pathway biology into differentiated drug candidates," said Kristina Masson, Ph.D., co-founder and EVP at Acrivon, and president and CEO of the company’s research subsidiary, Acrivon AB, in Lund, Sweden. "Our presentations underscore how AP3 moves beyond traditional target-centric drug discovery by directly measuring drug-regulated pathway activity in intact cells, enabling optimal biology-based design of compounds for superior clinical activity and patient benefit. ACR-2316 is a compelling example of this strategy, and we look forward to sharing our findings at the conference."

ACR-2316 is currently in a Phase 1/2 clinical study advancing toward the dose expansion phase. Initial observations have shown tumor shrinkage, including PRs, and durable clinical benefit in subjects with small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), and adenosarcoma NSCLC (adNSCLC), AP3-predicted tumor types not previously shown to be sensitive to other clinical WEE1 or PKMYT1 inhibitors. The compound has also demonstrated a favorable, differentiated tolerability profile observed in studies conducted to date, with adverse events primarily limited to only transient, mechanism-based neutropenia and a notable absence of non-hematological adverse events.

Presentations and Details

Oral Podium Presentation

Title: Acrivon Predictive Precision Proteomics (AP3): Next Generation Precision Medicine for Phosphoproteomics-Guided Drug Discovery
Presenter: Lei Shi, Ph.D., Director and Head, AP3 Pathway Discovery, Acrivon Therapeutics
Session: Biotech Spotlight Session 1: Novel Therapeutics
Date and Time: Thursday, July 23, 2026, 3:50–4:00 p.m. ET
Location: Grand Ballroom

Poster Presentation

Title: AP3-guided biological SAR enables discovery of ACR-2316, a novel clinical-stage WEE1/PKMYT1 inhibitor designed for CDK1/2 and PLK1 pathway activation
Poster Number: A082
Session: Poster Session A
Date and Time: Wednesday, July 22, 2026, 6:15–8:45 p.m. ET
Location: Back Bay Ballroom

(Press release, Acrivon Therapeutics, JUL 21, 2026, View Source [SID1234669359])

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

On July 21, 2026 Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, reported 2026 successes to date and provided an update on the Company’s upcoming milestones.

"Calidi continues to execute on its goal of bringing its RedTail platform to the clinic and expanding the utility of this groundbreaking technology," said Calidi Chief Executive Officer Eric Poma, PhD. "We have had productive discussions with the FDA that support our strategy and timeline for CLD-401 IND filing and we continue to expand the reach of RedTail with the development of in situ TCEs."

1H26 Accomplishments

Successful pre-IND meeting with FDA with agreement on pharmacology, toxicology, CMC, and phase I protocol strategy for CLD-401 phase I trial
In Situ TCEs have the potential to overcome current limitations around T-cell engagers in solid tumors by their ability to deliver high levels of a TCE in situ while simultaneously activating T-cells in the tumor microenvironment. Proof-of-concept data presented in 2026 underscore this potential
Strengthened the Board of Directors with the addition of Corsee Sanders, Ph.D. Dr. Sanders has served as strategic advisor to Celgene’s Chief Medical Officer (CMO) following Celgene’s acquisition of Juno where she was an Executive Vice President of Development Operations. She also served as Transition Advisor to Bristol Myers Squibb (BMS), which acquired Celgene. Prior to that, Dr. Sanders held numerous leadership positions over the course of 23 years at Genentech/Roche, including serving as Senior Vice President, Global Head of Clinical Operations and Industry Collaboration, for six years
Reduced debt and G&A expenses by approximately $1M in 1Q26 over 1Q25. Company will maintain a continued focus on cost cutting to ensure sufficient capital to advance pipeline
Upcoming Key Value Drivers

New data to be presented quantifying positive results from cytotoxicity and IL-15 SA expression in murine tumor cells at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Drug Discovery and Development (AACR D3) conference being held in Boston, MA from July 21-24, 2026
New data to be presented expanding in situ TCEs from the RedTail platform to include EpCAM-targeted TCEs, in addition to TROP-2, at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) conference being held in Madrid, Spain from October 23-27, 2026
New data to be presented including results from GLP toxicity and IND-enabling studies, as agreed to with the FDA at June 2026 pre-IND meeting, at the Society for Immunology of Cancer (SITC) (Free SITC Whitepaper) conference being held in Phoenix, AZ from November 4-8, 2026
Company targeting first patient dosed in CLD-401 phase I trial in Q1 2027. On track for regulatory submissions with positive feedback from FDA in pre-IND meeting
First patients’ data in CLD-401 trial anticipated in Q2 2027. The Company believes that early signs of activity and expression in tumor microenvironment (TME) would prove the platform is working as designed and viral and protein payloads are being effectively deployed in the TME

(Press release, Calidi Biotherapeutics, JUL 21, 2026, View Source [SID1234669358])

European Patent Office Confirms Patent Protection for SOT201, SOTIO’s Clinical-Stage Immunocytokine Showing Promising Anti-Tumor Activity

On July 21, 2026 SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, reported that the Boards of Appeal of the European Patent Office (EPO) have upheld European Patent EP 3 444 271 B1, reinforcing intellectual property protection for SOT201, the company’s next-generation PD-1-targeting immunocytokine currently being evaluated in a Phase 1 clinical trial. The decision strengthens the intellectual property foundation supporting a program that has already demonstrated a high disease control rate, including objective responses in heavily pre-treated cancer patients.

During oral proceedings held in the beginning of July, the Boards of Appeal confirmed the validity of the patent and upheld the earlier Opposition Division decision maintaining the patent as granted. The patent is co-owned by Cytune Pharma (an affiliate of SOTIO Biotech), AP-HP (Assistance Publique – Hôpitaux de Paris), and INSERM (Institut National de la Santé et de la Recherche Médicale). Opposition proceedings were initiated by Sanofi and Strawman Limited, and the subsequent appeal was filed by Sanofi.

The patent covers immunocytokines comprising a conjugate of interleukin-15 (IL-15) with the sushi domain of the IL-15 receptor alpha and an immunomodulatory antibody, including PD-1 antagonists. The decision further strengthens protection of SOTIO’s proprietary immunocytokine platform and the SOT201 program.

"We are pleased that the Boards of Appeal have upheld this important patent," said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. "The decision validates the strength of the underlying invention and reinforces the intellectual property supporting SOT201. Importantly, this milestone comes as the program continues to generate encouraging clinical data, including objective responses in heavily pre-treated patients, underscoring the potential of this novel immunocytokine approach."

SOT201 is a PD-1-targeted, cis-acting attenuated IL-15 agonist designed to preferentially activate PD-1+CD8+ T cells and enhance anti-tumor immune responses. The investigational therapy is currently being evaluated in the international Phase 1 VICTORIA-01 study in patients with advanced unresectable or metastatic solid tumors.

(Press release, SOTIO, JUL 21, 2026, View Source [SID1234669357])

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!

Month: July 2026

Vaxart to Participate in BTIG Biotechnology Conference 2026

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

European Patent Office Confirms Patent Protection for SOT201, SOTIO’s Clinical-Stage Immunocytokine Showing Promising Anti-Tumor Activity